OTC Watch

All stocks / PRPH

ProPhase Labs, Inc. PRPH

ProPhase Labs (PRPH): financing deals mentioned in an 8-K in January 2026, a late 10-Q notice in November 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Late filingEstimated floatCostly financing OTCIDNew York, USA
Live quote on OTC Markets

Market listing

Full name
PROPHASE LABS INC
Market tier
OTC Pink Current
Trading status
Active
Last trade
09:32:09
Website
www.quigleyco.com/
Source: Stockwatch, 2026-11-17

News headlines

ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
2026-04-15 09:05 · News Release
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
2026-03-17 08:00 · News Release
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart(TM) and Advances Crown Medical Collections Initiative
2026-02-03 07:00 · News Release
Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on February 3rd
2026-02-02 08:00 · News Release
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
2026-01-26 07:00 · News Release
ProPhase Labs Uplists from Pink Sheets to OTC Market
2026-01-22 07:00 · News Release
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
2026-01-05 05:00 · News Release
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
2025-12-19 07:00 · News Release
Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1
2025-11-26 08:00 · News Release
ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.
2025-11-19 08:13 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$4,345,000
Net loss
($14,743,000)
What it means

It spends more than it earns

Under strain

Customers paid it $4.3 million in the year. It lost $14.7 million. For every $1 that came in, about $4.39 went out.

The report says
Cash and cash equivalents
$90,000
Net cash used in operating activities
($8,344,000)
What it means

The cash could run out soon

Under strain

It had $90,000 in the bank and used about $695,333 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$59,871,000
Total liabilities
$56,363,000
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $59.9 million. Its debts and unpaid bills add up to $56.4 million. That is about $0.94 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Late filing2026-11-16

Filed NT 10-Q on 2026-11-16: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Estimated float2026-08-17

Estimated float about 15,592,556 shares as of 2026-08-17: 15,592,556 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Late filing2026-08-14

Filed NT 10-Q on 2026-08-14: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Late filing2026-05-15

Filed NT 10-Q on 2026-05-15: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Late filing2026-03-27

Filed NT 10-K on 2026-03-27: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Costly financing2026-01-23

8-K filed 2026-01-23 mentions: equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-09-30
41.5M
2025-11-17
46.2M
2025-12-31
9.0M
2026-03-31
14.0M
2026-05-29
14.0M
2026-06-29
14.0M
2026-06-30
14.0M
2026-08-17
15.6M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 NT 10-QNT 10-Q
2026-10-19 SCHEDULE 13G
2026-08-19 10-Q10-Q
2026-08-14 NT 10-QNT 10-Q
2026-08-06 8-K8-K
2026-07-09 10-Q/A10-Q/A
2026-07-07 10-Q/A10-Q/A
2026-06-30 10-Q10-Q
2026-06-01 10-K10-K
2026-05-15 NT 10-QNT 10-Q
2026-03-27 NT 10-KNT 10-K
2026-02-13 8-K8-K

Common questions about PRPH

Does PRPH file reports with the SEC?

Yes. ProPhase Labs files with the SEC under company number 0000868278. The most recent filing we hold is a NT 10-Q dated 2026-11-16.

Source record

How many PRPH shares are outstanding?

15,592,556 shares as of 2026-08-17, as reported to the SEC.

Source record

Has PRPH filed reports late?

Yes. In the last 12 months it filed 4 late-filing notices, most recently a NT 10-Q on 2026-11-16. A notice means a report was not ready on time; check whether the report followed.

Source record

Is ProPhase Labs making money?

Customers paid it $4.3 million in the year. It lost $14.7 million. For every $1 that came in, about $4.39 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record